Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Callitas Health Inc is a clinical-stage company. It is engaged in developing technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The company's products offering includes ToConceive, C-103 Reformulated Orlistat, and Extrinsa. ToConceive is a fertility enhancing moisturizer. It is clinically proven to increase a woman's own natural conception lubrication, called transudate, to aid in conception. Orlistat is FDA-approved for weight management and sold by Roche as Xenical (prescription) and by GlaxoSmithKline as alli. Extrinsa focuses on women with orgasm and arousal difficulties. The topical, local, and the non-systemic product is also non-hormonal and does not affect the central nervous system.
Vancouver, BC, V7X 1B1, Canada